CeriBell, Inc. logo CBLL - CeriBell, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 4
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $27.50 DETAILS
HIGH: $30.00
LOW: $25.00
MEDIAN: $27.50
CONSENSUS: $27.50
UPSIDE: 46.51%

Stock News

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.

May 20, 2026 12:05 PM • globenewswire.com
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026

Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.

Apr 20, 2026 12:05 PM • globenewswire.com
CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot

CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot

CeriBell (NASDAQ: CBLL) executives outlined the company's 2026 priorities and growth drivers during a fireside chat at the 46th annual TD Cowen Healthcare Conference, emphasizing continued expansion in hospital adoption, upcoming pediatric and neonatal offerings, early plans for a delirium commercialization pilot, and efforts to maintain strong gross margins amid shifting tariff dynamics. 2026 outlook and

Mar 08, 2026 09:02 PM • defenseworld.net
CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium

CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium

CeriBell (NASDAQ: CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told investors the company ended 2025 with $89 million in revenue, representing 36% year-over-year growth, and

Mar 08, 2026 09:02 PM • defenseworld.net
Allurion Technologies (NYSE:ALUR) & CeriBell (NASDAQ:CBLL) Head-To-Head Survey

Allurion Technologies (NYSE:ALUR) & CeriBell (NASDAQ:CBLL) Head-To-Head Survey

CeriBell (NASDAQ: CBLL - Get Free Report) and Allurion Technologies (NYSE: ALUR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Recommendations This is a breakdown of recent

Mar 01, 2026 09:34 PM • defenseworld.net
Ceribell to Participate in Upcoming March Investor Conferences

Ceribell to Participate in Upcoming March Investor Conferences

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:50 a.m. Pacific Standard Time / 1:50 p.m. Eastern Standard Time.

Feb 18, 2026 11:05 AM • globenewswire.com
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.

Feb 10, 2026 11:05 AM • globenewswire.com

Price Targets